HIV associated nephropathy natural history, complications and prognosis

Jump to navigation Jump to search

HIV associated nephropathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating HIV associated nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

KUB X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

HIV associated nephropathy natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV associated nephropathy natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV associated nephropathy natural history, complications and prognosis

CDC on HIV associated nephropathy natural history, complications and prognosis

HIV associated nephropathy natural history, complications and prognosis in the news

Blogs on HIV associated nephropathy natural history, complications and prognosis

Directions to Hospitals Treating HIV associated nephropathy

Risk calculators and risk factors for HIV associated nephropathy natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[3]Krzysztof Wierzbicki M.D. [4]

Overview

HIV-associated nephropathy (HIVAN) will progress to end stage renal disease (ESRD) in a few weeks to months without treatment. However, early diagnosis and treatment has shown better outcome.

Natural History

  • If left untreated, HIV-associated nephropathy (HIVAN) will progress to end stage renal disease (ESRD) in a few weeks to months.[1]
  • Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
  • Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
  • Early diagnosis and Immediate treatment has shown better outcome.[1]

Complications

Possible complications that are associated with HIV-associated nephropathy include:

Prognosis

  • Before the advent of cART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months.[1]
  • Today, the prognosis of HIVAN with the availability of cART therapy still remains grim,[1] however, treatment with cART has increased renal survival rate.[2]
  • Early diagnosis and Immediate treatment has shown better outcome.[1]
  • Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
  • Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
  • The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy.[3]
  • Several factors have been associated with increased risk of progression of kidney disease in patients with HIVAN, which include:[4]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Atta MG, Lucas GM, Fine DM (2008). "HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management". Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.
  2. Atta MG, Fine DM, Kirk GD, Mehta SH, Moore RD, Lucas GM (2007). "Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland". Clin Infect Dis. 45 (12): 1625–32. doi:10.1086/523728. PMC 4096866. PMID 18190325.
  3. Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N; et al. (2005). "Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy". Am J Med. 118 (11): 1288. doi:10.1016/j.amjmed.2005.05.027. PMID 16271919.
  4. Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA; et al. (2018). "HIV-associated nephropathy: links, risks and management". HIV AIDS (Auckl). 10: 73–81. doi:10.2147/HIV.S141978. PMC 5975615. PMID 29872351.

Template:WH Template:WS